Format

Send to

Choose Destination
Br J Haematol. 2015 Oct;171(2):189-196. doi: 10.1111/bjh.13537. Epub 2015 Jun 30.

Trends in survival of multiple myeloma patients in Germany and the United States in the first decade of the 21st century.

Author information

1
Division of Clinical Epidemiology and Aging Research, German Cancer Research Centre (DKFZ), Heidelberg, Germany.
2
Cardeza Foundation and Division of Hematology, Department of Medicine, Thomas Jefferson University, Philadelphia, PA, USA.
3
Cancer Registry of Rhineland-Palatinate, Institute for Medical Biostatistics, Epidemiology and Informatics, University Medical Centre, Johannes Gutenberg University Mainz, Mainz, Germany.
4
Cancer Registry of Schleswig-Holstein, Lübeck, Germany.
5
Saarland Cancer Registry, Saarbrücken, Germany.
6
German Cancer Consortium (DKTK), German Cancer Research Centre, Heidelberg, Germany.

Abstract

Multiple myeloma is a chronic, incurable but highly treatable neoplasm. Recent population-based studies have shown improvements in survival for patients diagnosed in the early 21st century. Here, we examine trends in survival for patients diagnosed with multiple myeloma in Germany and the United States (US) between 2002 and 2010. Data were extracted from 11 population-based cancer registries in Germany and from the Surveillance, Epidemiology and End Results database in the US. Myeloma patients aged 15-74 years with diagnosis and follow-up between 1997 and 2010 from Germany and the US were included. Period analysis was employed to assess trends in 5-year relative survival in Germany and the US between 2002-04 and 2008-10. Age-adjusted 5-year relative survival increased from 47·3% to 53·8% in Germany and from 39·8% to 53·2% in the US between 2002-04 and 2008-10. There was a strong age gradient with lower survival among older patients, which persisted over time and was more pronounced in Germany than the US. Five-year relative survival estimates for patients diagnosed with multiple myeloma below 75 years of age steadily increased throughout the first decade of the 21st century and reached levels above 50% in both Germany and the US, probably reflecting the increased use of newer agents in myeloma treatment.

KEYWORDS:

myeloma; period analysis; survival

PMID:
26123295
DOI:
10.1111/bjh.13537
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center